Vonoprazan
- Generic Name
- Vonoprazan
- Brand Names
- Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500
- Drug Type
- Small Molecule
- Chemical Formula
- C17H16FN3O2S
- CAS Number
- 881681-00-1
- Unique Ingredient Identifier
- 1R5L3J156G
- Background
Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits H, K-ATPase-mediated gastric acid secretion. PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders. Unlike proton-pump inhibitors, PCABs are not affected by CYP2C19 genetic polymorphisms and do not require acid-resistant formulations. Furthe...
- Indication
Vonoprazan, in combination with amoxicillin and clarithromycin in a co-packaged product, is indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults. Another co-packaged product with only vonoprazan and amoxicillin is also indicated for the treatment of H. pylori infection in adults.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastric or Duodenal Ulcers Caused by Low-dose Aspirin, Helicobacter Pylori Infection, Reflux Esophagitis (RE), Develop NSAID-induced gastric ulcers
- Associated Therapies
- -
Vonoprazan for Helicobacter Pylori Eradication in Adolescents
- Conditions
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 242
- Registration Number
- NCT06162949
- Locations
- 🇪🇬
Faculty of Medicine, Alexandria, Egypt
A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT06106022
- Locations
- 🇺🇸
Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States
🇺🇸Children's Center for Digestive Health Care, LLC, Atlanta, Georgia, United States
🇺🇸Maspons Pediatric Gastro, El Paso, Texas, United States
Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 232
- Registration Number
- NCT06101420
- Locations
- 🇪🇬
Faculty of Medicine Ain Shams University, Cairo, Egypt
High-dose Dual Therapy With Different Administration Frequencies
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 327
- Registration Number
- NCT05901051
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Rescue Therapy for Helicobacter Pylori Infection
- Conditions
- Interventions
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 357
- Registration Number
- NCT05874544
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
🇨🇳Shanghai Songjiang District Central Hospital, Shanghai, Shanghai, China
🇨🇳The Second Affiliated Hospital of Zhejiang University school of Medicine, Hangzhou, Zhejiang, China
Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Shanghai East Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05726734
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
The Effect of Probiotics on Gut Microbiotain After Helicobacter Pylori Eradication
- Conditions
- Interventions
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2023-02-08
- Target Recruit Count
- 100
- Registration Number
- NCT05658055
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
Optimization of Vonoprazan-based Dual Therapy for Helicobacter Pylori
- Conditions
- Interventions
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2024-11-19
- Target Recruit Count
- 900
- Registration Number
- NCT05649540
- Locations
- 🇨🇳
Changzhou Traditional Chinese Medicine Hospital, Changzhou, Jiangsu, China
🇨🇳Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳The Affiliated Zhangjiagang Hospital of Soochow University, Zhangjiagang, Jiangsu, China
PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 594
- Registration Number
- NCT05582174
- Locations
- 🇨🇳
Nanfang Hospital Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Shenzhen Pingshan District People's Hospital, Shenzhen, Guangdong, China
🇨🇳The Second Affiliated Hospital The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, Shenzhen, Guangdong, China
Efficacy and Safety of Dual Therapy for Helicobacter Pylori Eradication
- Conditions
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-06-13
- Target Recruit Count
- 914
- Registration Number
- NCT05469685
- Locations
- 🇨🇳
Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
🇨🇳Changshu No.1 People's Hospital, Suzhou, Jiangsu, China
🇨🇳Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.